Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin.

Next Previous
X
Search
Trial Profile

Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verubulin (Primary) ; Carboplatin
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Myrexis

    • Most Recent Events

    • 24 Mar 2011 Planned end date changed from 1 Aug 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 28 May 2010 Updated information on this trial will be presented as a poster at ASCO 2010, according to a Myriad Pharmaceuticals media release.
    • 20 May 2010 19 patients have been accrued to this study as at 7 December 2009, according to a Myriad Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top